137 related articles for article (PubMed ID: 16952039)
21. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Giuliani F; Molica S; Maiello E; Battaglia C; Gebbia V; Di Bisceglie M; Vinciarelli G; Gebbia N; Colucci G;
Am J Clin Oncol; 2005 Dec; 28(6):581-5. PubMed ID: 16317268
[TBL] [Abstract][Full Text] [Related]
22. [Clinical efficacy of low-dose CDDP and CPT-11 therapy as second- or third-line chemotherapy for advanced and recurrent gastric cancer].
Ito S; Takagawa R; Minami Y; Watanabe J; Morita T; Mogaki M; Masui H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1107-11. PubMed ID: 25248893
[TBL] [Abstract][Full Text] [Related]
23. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Park SH; Choi EY; Bang SM; Cho EK; Lee JH; Shin DB; Ki Lee W; Chung M
Anticancer Drugs; 2005 Jul; 16(6):621-5. PubMed ID: 15930889
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Bamias A; Papamichael D; Syrigos K; Pavlidis N
J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer.
Imamura H; Ikeda M; Furukawa H; Tsujinaka T; Fujitani K; Kobayashi K; Narahara H; Kato M; Imamoto H; Takabayashi A; Tsukuma H
World J Gastroenterol; 2006 Oct; 12(40):6522-6. PubMed ID: 17072984
[TBL] [Abstract][Full Text] [Related]
27. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
[TBL] [Abstract][Full Text] [Related]
28. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.
Chitapanarux I; Tonusin A; Sukthomya V; Charuchinda C; Pukanhapan N; Lorvidhaya V
Gynecol Oncol; 2003 Jun; 89(3):402-7. PubMed ID: 12798702
[TBL] [Abstract][Full Text] [Related]
29. Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
Satoh S; Kawashima K; Matsumoto S; Hasegawa S; Okabe H; Nomura A; Yoshibayashi H; Watanabe G; Nagayama S; Fukushima M; Sakai Y
Chemotherapy; 2007; 53(3):226-32. PubMed ID: 17356271
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
Im CK; Rha SY; Jeung HC; Ahn JB; Shin SJ; Noh SH; Roh JK; Chung HC
Am J Clin Oncol; 2010 Feb; 33(1):56-60. PubMed ID: 19730355
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.
Jeung HC; Rha SY; Noh SH; Roh JK; Chung HC
Cancer Chemother Pharmacol; 2007 Feb; 59(3):313-20. PubMed ID: 16770582
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Baba E; Esaki T; Ariyama H; Mitsugi K; Morikita T; Fujishima H; Kusaba H; Nakano S; Akashi K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):611-7. PubMed ID: 21116623
[TBL] [Abstract][Full Text] [Related]
34. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
Newman E; Marcus SG; Potmesil M; Sewak S; Yee H; Sorich J; Hayek M; Muggia F; Hochster H
J Gastrointest Surg; 2002; 6(2):212-23; discussion 223. PubMed ID: 11992807
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
[TBL] [Abstract][Full Text] [Related]
38. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Shimoyama R; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N; Todaka A; Tomita H; Sakamoto T; Tsushima T
Gastric Cancer; 2009; 12(4):206-11. PubMed ID: 20047125
[TBL] [Abstract][Full Text] [Related]
39. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
[TBL] [Abstract][Full Text] [Related]
40. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Higuchi K; Tanabe S; Shimada K; Hosaka H; Sasaki E; Nakayama N; Takeda Y; Moriwaki T; Amagai K; Sekikawa T; Sakuyama T; Kanda T; Sasaki T; Azuma M; Takahashi F; Takeuchi M; Koizumi W;
Eur J Cancer; 2014 May; 50(8):1437-45. PubMed ID: 24560487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
